Lifecore Biomedical
LFCR55
$7.31arrow_drop_up4.58%$0.31
LFCR55
$7.31
arrow_drop_up4.58%Performance History
| Key Stats | |
|---|---|
| Open | $7.14 |
| Prev. Close | $6.98 |
| EPS | 0.13 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 6.96 | 7.45 |
| 52 Week Range | 3.68 | 8.90 |
| Ratios | |
|---|---|
| EPS | 0.13 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Lifecore Biomedical (LFCR)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. James G. Hall
- Headquarters
- Chaska
- Employees
- 689
- Exchange
- NASDAQ
Keep an eye on Lifecore Biomedical
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Lifecore Biomedical's (LFCR) price per share?
The current price per share for Lifecore Biomedical (LFCR) is $7.31. The stock has seen a price change of $0.32 recently, indicating a 4.58% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Lifecore Biomedical (LFCR)?
For Lifecore Biomedical (LFCR), the 52-week high is $8.9, which is 21.75% from the current price. The 52-week low is $3.68, the current price is 98.64% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Lifecore Biomedical (LFCR) a growth stock?
Lifecore Biomedical (LFCR) has shown an average price growth of -3.66% over the past three years. It has received a score of 36 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lifecore Biomedical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Lifecore Biomedical (LFCR) stock price performance year to date (YTD)?
As of the latest data, Lifecore Biomedical (LFCR) has a year-to-date price change of 14.58%. Over the past month, the stock has experienced a price change of 37.66%. Over the last three months, the change has been 21.83%. Over the past six months, the figure is 28.47%.
help
Is Lifecore Biomedical (LFCR) a profitable company?
Lifecore Biomedical (LFCR) has a net income of $9.33M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 32.63% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -36.77% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $128.26M, although specific revenue growth data is currently not available. The gross profit is $41.85M. Operating income is noted at $9.33M. Furthermore, the EBITDA is -$674K.
help
What is the market capitalization of Lifecore Biomedical (LFCR)?
Lifecore Biomedical (LFCR) has a market capitalization of $269.21M. The average daily trading volume is 7.27, indicating the stock's liquidity and investor engagement.
News
LIFECORE BIOMEDICAL
CDMO
INVESTOR DAY
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
LIFECORE BIOMEDICAL
CDMO
OPERATIONS
QUALITY
REGULATORY COMPLIANCE
GROWTH STRATEGY
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations
PALVELLA THERAPEUTICS
MATTHEW E. KORENBERG
CHIEF FINANCIAL OFFICER
LIGAND PHARMACEUTICALS
LIFECORE BIOMEDICAL
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
HYALURONIC ACID
COSMETICS
OSTEOARTHRITIS
EYE CARE
MARKET GROWTH
Hyaluronic Acid Market Driven by Increasing Demand for Cosmetics and Expected to Grow over 21 Bn by 2032
LIFECORE BIOMEDICAL
FINANCIAL RESULTS
CAPACITY EXPANSION
NEW BUSINESS AGREEMENTS
FINANCING
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
LIFECORE BIOMEDICAL
LINDY BIOSCIENCES
MICROGLASSIFICATION
BIOLOGIC THERAPEUTICS
Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology